Lymphoid enhancer-binding factor 1 mRNA 3' untranslated region (LEF1 mRNA 3' UTR)

Lymphoid enhancer-binding factor 1 (LEF1) is a key transcription factor within the Wnt/beta-catenin signaling pathway, playing a vital role in cell lineage commitment, proliferation, and survival (UniProt P17535). The 3' untranslated region (3' UTR) of the LEF1 mRNA is a significant regulatory segment that controls the expression levels of the LEF1 protein by serving as a binding site for various microRNAs (miRNAs) and RNA-binding proteins (PubMed: 22508259). Dysregulation of this region, such as the loss of miRNA-mediated repression, leads to the pathological overexpression of LEF1, which is a hallmark of several cancers, most notably chronic lymphocytic leukemia (CLL) and colorectal carcinoma (PubMed: 23873017). Therapeutic strategies targeting the LEF1 mRNA 3' UTR involve the use of miRNA mimics, such as miR-26b or miR-34a, and antisense oligonucleotides designed to induce mRNA degradation or block translation (PubMed: 25670454). While clinical applications are primarily in the experimental stage, targeting this regulatory region offers a high degree of specificity for modulating the Wnt pathway in oncogenic contexts. Challenges include the efficient delivery of RNA-based therapeutics and the potential for off-target effects due to the broad regulatory networks of miRNAs. For instance, the clinical trial for the miR-34a mimic MRX34 was halted due to severe immune-related adverse events, highlighting the safety hurdles in targeting these pathways (NCT01829971).

Other names

LEF-1 3' UTRLEF1 3-prime untranslated regionLymphoid enhancer-binding factor 1 3' UTRLEF1 mRNA regulatory region

Modulation of mRNA stability and translation through RNA interference or antisense binding to regulatory sequences, leading to the downregulation of LEF1 protein expression.